Omnicell publishes investor presentation outlining autonomous pharmacy strategy, Titan XT and OmniSphere platform rollout
OMCL•Backlog and annual recurring revenue
Product backlog of $640 million and annual recurring revenue of $636 million as of Dec. 31, 2025.
Recurring revenue and financial position
Recurring revenue emphasis is through SaaS and expert services, with recurring revenue projected at 22% of total revenue in 2026.
The balance sheet is described as strong, framed as supporting growth initiatives and a push toward sustainable, profitable growth.
Autonomous pharmacy strategy and platform rollout
Omnicell outlined a strategy centered on autonomous medication management, prioritizing connected automation, innovation-led pharmacy workflows, and expansion across care settings.
The next-generation Titan XT automated dispensing system, powered by the OmniSphere cloud platform, is positioned as the core of an enterprise-wide medication management architecture.
